ARTICLE | Distillery Therapeutics

Therapeutics: Heat shock protein 70 (Hsp70)

January 15, 2015 8:00 AM UTC

In vitro and mouse studies identified an inducible Hsp70 inhibitor that could help treat cancer. In breast and prostate cancer cell lines, a selective allosteric Hsp70 inhibitor decreased proliferation compared with treated non-malignant cells. In a mouse model of HER2-overexpressing breast cancer, intraperitoneal injection of the Hsp70 inhibitor decreased tumor growth and increased median survival compared with untreated controls. Next steps could include testing the inhibitor in additional cancer models.

Minneamrita Therapeutics LLC has the Hsp70 inhibitor minnelide in Phase I to treat gastrointestinal cancer. ...